Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. Among authors: shcherbinin s. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I, Willis BA, Chua L, Chow K, Ernest CS 2nd, Wang J, Shcherbinin S, Sims JR, Chigutsa E. Gueorguieva I, et al. Among authors: shcherbinin s. Alzheimers Dement (N Y). 2023 Jun 28;9(2):e12404. doi: 10.1002/trc2.12404. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37388759 Free PMC article.
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Shcherbinin S, Morris A, Higgins IA, Tunali I, Lu M, Deveau C, Southekal S, Kotari V, Evans CD, Arora AK, Collins EC, Pontecorvo M, Mintun MA, Sims JR. Shcherbinin S, et al. Alzheimers Dement (N Y). 2023 Aug 16;9(3):e12415. doi: 10.1002/trc2.12415. eCollection 2023 Jul-Sep. Alzheimers Dement (N Y). 2023. PMID: 37600216 Free PMC article.
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.
Zheng L, Rubinski A, Denecke J, Luan Y, Smith R, Strandberg O, Stomrud E, Ossenkoppele R, Svaldi DO, Higgins IA, Shcherbinin S, Pontecorvo MJ, Hansson O, Franzmeier N, Ewers M; Alzheimer's Disease Neuroimaging Initiative. Zheng L, et al. Among authors: shcherbinin s. Ann Neurol. 2024 Feb;95(2):274-287. doi: 10.1002/ana.26818. Epub 2023 Oct 25. Ann Neurol. 2024. PMID: 37837382
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A, Biel D, Dewenter A, Roemer S, Wagner F, Dehsarvi A, Rathore S, Otero Svaldi D, Higgins I, Brendel M, Dichgans M, Shcherbinin S, Ewers M, Franzmeier N. Steward A, et al. Among authors: shcherbinin s. JAMA Neurol. 2023 Dec 1;80(12):1295-1306. doi: 10.1001/jamaneurol.2023.4038. JAMA Neurol. 2023. PMID: 37930695
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
Chen CD, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay NS, Hobbs DA, Hornbeck R, Fagan AM, Cruchaga C, Goate AM, Perrin RJ, Wang G, Li Y, Shi X, Xiong C, Pontecorvo MJ, Klein G, Su Y, Klunk WE, Jack C, Koeppe R, Snider BJ, Berman SB, Roberson ED, Brosch J, Surti G, Jiménez-Velázquez IZ, Galasko D, Honig LS, Brooks WS, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters CL, van Dyck CH, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford DB, Mills S, Supnet-Bell C, McDade E, Bateman RJ, Benzinger TLS; DIAN-TU Study Team. Chen CD, et al. Among authors: shcherbinin s. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 37017737 Free PMC article. Clinical Trial.
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, Otero Svaldi D, Higgins IA, Pontecorvo M, Römer S, Steward A, Rubinski A, Zheng L, Schöll M, Shcherbinin S, Ewers M, Franzmeier N; Alzheimer’s Disease Neuroimaging Initiative. Biel D, et al. Among authors: shcherbinin s. Alzheimers Res Ther. 2022 Nov 7;14(1):166. doi: 10.1186/s13195-022-01105-5. Alzheimers Res Ther. 2022. PMID: 36345046 Free PMC article.
73 results